297 related articles for article (PubMed ID: 8634987)
1. Chemoprevention trials and surrogate end point biomarkers in the cervix.
Mitchell MF; Hittelman WK; Lotan R; Nishioka K; Tortolero-Luna G; Richards-Kortum R; Wharton JT; Hong WK
Cancer; 1995 Nov; 76(10 Suppl):1956-77. PubMed ID: 8634987
[TBL] [Abstract][Full Text] [Related]
2. Strategies for phase II cancer chemoprevention trials: cervix, endometrium, and ovary.
Kelloff GJ; Boone CW; Crowell JA; Nayfield SG; Hawk E; Steele VE; Lubet RA; Sigman CC
J Cell Biochem Suppl; 1995; 23():1-9. PubMed ID: 8747372
[TBL] [Abstract][Full Text] [Related]
3. Biomarkers and their use in cervical cancer chemoprevention.
Vlastos AT; Schottenfeld D; Follen M
Crit Rev Oncol Hematol; 2003 Jun; 46(3):261-73. PubMed ID: 12791426
[TBL] [Abstract][Full Text] [Related]
4. Chemoprevention trials in the cervix: design, feasibility, and recruitment.
Mitchell MF; Hittelman WN; Lotan R; Nishioka K; Tortolero-Luna G; Richards-Kortum R; Hong WK
J Cell Biochem Suppl; 1995; 23():104-12. PubMed ID: 8747384
[TBL] [Abstract][Full Text] [Related]
5. Epidermal growth factor receptor expression in cervical intraepithelial neoplasia and its modulation during an alpha-difluoromethylornithine chemoprevention trial.
Boiko IV; Mitchell MF; Hu W; Pandey DK; Mathevet P; Malpica A; Hittelman WN
Clin Cancer Res; 1998 Jun; 4(6):1383-91. PubMed ID: 9626454
[TBL] [Abstract][Full Text] [Related]
6. Surrogate endpoint biomarkers for cervical cancer chemopreventive trials.
Ruffin MT; Ogaily MS; Johnston CM; Gregoire L; Lancaster WD; Brenner DE
J Cell Biochem Suppl; 1995; 23():113-24. PubMed ID: 8747385
[TBL] [Abstract][Full Text] [Related]
7. Development of difluoromethylornithine (DFMO) as a chemoprevention agent.
Meyskens FL; Gerner EW
Clin Cancer Res; 1999 May; 5(5):945-51. PubMed ID: 10353725
[TBL] [Abstract][Full Text] [Related]
8. DNA image cytometric measurement as a surrogate end point biomarker in a phase I trial of alpha-difluoromethylornithine for cervical intraepithelial neoplasia.
Boiko IV; Mitchell MF; Pandey DK; White RA; Hu W; Malpica A; Nishioka K; Boone CW; Atkinson EN; Hittelman WN
Cancer Epidemiol Biomarkers Prev; 1997 Oct; 6(10):849-55. PubMed ID: 9332769
[TBL] [Abstract][Full Text] [Related]
9. New agents for cancer chemoprevention.
Kelloff GJ; Boone CW; Crowell JA; Steele VE; Lubet RA; Doody LA; Malone WF; Hawk ET; Sigman CC
J Cell Biochem Suppl; 1996; 26():1-28. PubMed ID: 9154166
[TBL] [Abstract][Full Text] [Related]
10. Cervical chromosome 9 polysomy: validation and use as a surrogate endpoint biomarker in a 4-HPR chemoprevention trial.
Kim HG; Yamal JM; Xu XC; Hu W; Boiko I; Linares A; Vlastos AT; Atkinson EN; Malpica A; Hittelman WN; Follen M
Gynecol Oncol; 2005 Dec; 99(3 Suppl 1):S32-7. PubMed ID: 16154183
[TBL] [Abstract][Full Text] [Related]
11. Cancer risk factors for selecting cohorts for large-scale chemoprevention trials.
Greenwald P
J Cell Biochem Suppl; 1996; 25():29-36. PubMed ID: 9027595
[TBL] [Abstract][Full Text] [Related]
12. Progress in cancer chemoprevention: perspectives on agent selection and short-term clinical intervention trials.
Kelloff GJ; Boone CW; Steele VE; Crowell JA; Lubet R; Sigman CC
Cancer Res; 1994 Apr; 54(7 Suppl):2015s-2024s. PubMed ID: 8137331
[TBL] [Abstract][Full Text] [Related]
13. Risk biomarkers and current strategies for cancer chemoprevention.
Kelloff GJ; Boone CW; Crowell JA; Nayfield SG; Hawk E; Malone WF; Steele VE; Lubet RA; Sigman CC
J Cell Biochem Suppl; 1996; 25():1-14. PubMed ID: 9027592
[TBL] [Abstract][Full Text] [Related]
14. Executive Summary of the National Cancer Institute Workshop: Highlights and recommendations.
Lieberman R; Nelson WG; Sakr WA; Meyskens FL; Klein EA; Wilding G; Partin AW; Lee JJ; Lippman SM
Urology; 2001 Apr; 57(4 Suppl 1):4-27. PubMed ID: 11295590
[TBL] [Abstract][Full Text] [Related]
15. Why phase II trials in cervical chemoprevention are negative: what have we learned?
Follen M; Vlastos AT; Meyskens FL; Atkinson EN; Schottenfeld D
Cancer Causes Control; 2002 Nov; 13(9):855-73. PubMed ID: 12462551
[TBL] [Abstract][Full Text] [Related]
16. Retinoids for preventing the progression of cervical intra-epithelial neoplasia.
Helm CW; Lorenz DJ; Meyer NJ; Rising WW; Wulff JL
Cochrane Database Syst Rev; 2013 Jun; 2013(6):CD003296. PubMed ID: 23740788
[TBL] [Abstract][Full Text] [Related]
17. Chemoprevention of cancer.
Szarka CE; Grana G; Engstrom PF
Curr Probl Cancer; 1994; 18(1):6-79. PubMed ID: 8005001
[TBL] [Abstract][Full Text] [Related]
18. Surrogate endpoint biomarkers and their modulation in cervical chemoprevention trials.
Follen M; Schottenfeld D
Cancer; 2001 May; 91(9):1758-76. PubMed ID: 11335902
[TBL] [Abstract][Full Text] [Related]
19. Cancer chemoprevention. Part 1: Retinoids and carotenoids and other classic antioxidants.
Singh DK; Lippman SM
Oncology (Williston Park); 1998 Nov; 12(11):1643-53, 1657-8; discussion 1659-60. PubMed ID: 9834941
[TBL] [Abstract][Full Text] [Related]
20. Cancer chemoprevention. Part 2: Hormones, nonclassic antioxidant natural agents, NSAIDs, and other agents.
Singh DK; Lippman SM
Oncology (Williston Park); 1998 Dec; 12(12):1787-800; discussion 1802, 1805. PubMed ID: 9874850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
